Companies / ARX

AROA BIOSURGERY LIMITED

ASX:ARXPharmaceuticals, Biotechnology & Life Sciences
345.9M shares on issueASX (delayed) · as of 28 July 2026$0.58price · delayed$193.7Mmarket cap · indicative
A
Dilution grade

Options/rights overhang 9% of shares; 0% of shares in the money

Cash runway27.5 quarters of funding
Share-count growth (24m)0.5%
Raise cadence (24m)0 cash raises
Options & rights overhang9.1% of shares
In-the-money supply0.2% of shares
Pending proposed issuesnone

AROA BIOSURGERY LIMITED had 346M ordinary shares as of April 2026, up 0.5% since March 2024. There were no capital raises in the 24‑month window. Options and rights could convert into 31M new shares, equal to 9.1% of the current share count, with the nearest expiry in August 2026 and 0% in the money. At the September 2025 quarter the company reported A$28.3M in cash, representing 27.5 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
9.1%
Max option dilution
0.2%
ITM option dilution
0
Raises · last 12 months
27.5 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 345.9M per ASX (delayed) (28 July 2026).
345.1M345.4M345.7MDec 24Sept 25July 26

Cash runway

—
Cover not computed for the latest quarter.
$28.3M available cash at quarter ended 30 Sept 2025 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 Sept 2025.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
28 July 20263G · unquotedARX : ORDINARY FULLY PAID345.9MAppendix 3G
14 July 20263H · cancellationARX : ORDINARY FULLY PAID345.9MAppendix 3H
10 Apr 20262A · quoted issueARX : ORDINARY FULLY PAID345.9MAppendix 2A
9 Apr 20263H · cancellationARX : ORDINARY FULLY PAID345.5MAppendix 3H
3 Feb 20262A · quoted issueARX : ORDINARY FULLY PAID345.5MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

9.1%
Total overhang · of current shares
0.2%
In the money · at current price
31.3M
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
26 June 2026John DiddamsSell1.0M20k$126k3Y notice
20 Sept 2025Brian WardOther33.1M1.4M—3Y notice
23 July 2025John PinionSell473k633k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026Notification regarding unquoted securities - ARX
27 July 2026Commercial Leadership Appointments
24 July 2026Notice of Annual General Meeting/Proxy Form
14 July 2026Notification of cessation of securities - ARX
13 July 2026Symphony - Outpatient Reimbursement Update
9 July 2026Resignation of CFO and Joint Company Secretary
30 June 2026Appendix 4G and Corporate Governance Statement
30 June 2026Annual Report to Shareholders
29 June 2026Change of Director's Interest Notice - JD
23 June 2026Notice of AGM Date and Director Nomination Closing Date
27 May 2026Change in substantial holding
26 May 2026FY26 Full Year Results Presentation - Correction
25 May 2026$PFY26 Full Year Results Presentation
25 May 2026$PFY26 Appendix 4E and Full Year Results
18 May 2026Notification of Full Year Results Webinar
29 Apr 2026$PARX FY26 Preliminary Results
10 Apr 2026Application for quotation of securities - ARX
9 Apr 2026Notification of cessation of securities - ARX
29 Mar 2026$PSymphony Randomised Control Trial Complete
24 Mar 2026Release of Shares from Voluntary Escrow

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.